ALLISON MARTIN: Open Payments
NPI 1003527722 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,133 in 49 payments from 22 companies in 2025. Trend: 2023 $669 · 2024 $1,268 · 2025 $1,133
Food & beverage: $960Education: $173
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 7 | $147 |
| Incyte Corporation | 3 | $138 |
| PFIZER INC. | 6 | $101 |
| PharmaEssentia USA Corporation | 4 | $87 |
| SEAGEN INC. | 1 | $80 |
| Novartis Pharmaceuticals Corporation | 4 | $77 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| GENZYME CORPORATION | 2 | $45 |
| ABBVIE INC. | 2 | $41 |
| Genentech USA, Inc. | 2 | $40 |
Products named: KEYTRUDA, BESREMI, TAGRISSO, SCEMBLIX, XTANDI, IBRANCE, SARCLISA, REBLOZYL.
Industry payments across IN — which companies pay providers there.
